Navigation Links
Cepheid Reports 2013 Second Quarter Results
Date:7/18/2013

y, total sales were, in millions: Three Months Ended June 30,20132012ChangeNorth AmericaClinical

$
49.9$
47.55%Non-Clinical & Other

7.59.5-21%Total North America57.457.01%InternationalClinical

37.622.269%Non-Clinical & Other

1.01.8-41%Total International38.624.061%Total Sales$
96.0$
81.019%


  • During the quarter, Cepheid installed a total of 156 GeneXpert systems in its commercial Clinical business.  Additionally, the Company placed a total of 279 GeneXpert systems as part of its High Burden Developing Country (HBDC) program.  Including the HBDC systems, a cumulative total of 4,552 GeneXpert systems have been placed worldwide as of June 30, 2013.
  • GAAP gross margin on sales was 45% and non-GAAP gross margin on sales was 47%, which compares to 57% and 58%, respectively, in the second quarter of 2012.  Excluding the impact of the unanticipated inventory reserve of approximately $3.0 million, GAAP gross margin on sales was 48% and non-GAAP gross margin on sales was 50%.
  • Cash and cash equivalents were $85.0 million as of June 30, 2013.
  • DSO was 45 days.
  • Business OutlookFor the fiscal year ending December 31, 2013, the Company's full year guidance has been revised to reflect additional investment in manufacturing operations to fully prepare the Company to effectively manage growing demand and expected revenue mix between Commercial Clinical and HBDC.  With these points in mind, the Company now expects:

  • Total revenue in the range of $380 to $385 million;
  • Net loss in a range from $(0.30) to $(0.27) per share; and
  • Non-GAAP net income in the range of $0.18 to $0.21 per share. 
  • Expected non-GAAP net income excludes approximately $29 million related to stock compensation expense and approximately $4 million related to the amortization of acquired intangibles.  The fully diluted share count for the
    '/>"/>

    SOURCE Cepheid
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. Cepheid Welcomes Senior Vice President of Human Resources
    2. Cepheid Reports Fourth Quarter and Full Year 2011 Results
    3. Cepheid to Webcast Upcoming Financial Presentations
    4. Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria
    5. Diagnostic Marketing Association Names Cepheid 2011 Marketer of the Year
    6. Cepheid Announces European Release of Xpert CT/NG and Xpert CT, Delivering Rapid Detection and Differentiation of Chlamydia and Gonorrhoeae
    7. Cepheid Receives FDA Clearance for GeneXpert Infinity-80 System for Initial Use with Xpert Flu Assay
    8. Cepheid Reports 2012 Second Quarter Results
    9. Cepheid Announces Board of Directors Changes
    10. Testing Positive for Stability & Growth - Research Report on CombiMatrix Corporation, Cepheid, PerkinElmer, Inc., Life Technologies Corp. and Laboratory Corp. of America Holdings
    11. Cepheid Reports 2013 First Quarter Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/2/2015)... 2015 Outside GC, the leading provider ... addition of Debbie Casey as a member of the ... space. , Debbie has spent over 20 ... Fresenius Medical Care North America in both legal and ... to work with Outside GC’s growing list of healthcare ...
    (Date:2/27/2015)... Nova Scotia (PRWEB) February 27, 2015 ... been made aware of a fraudulent press release disseminated ... purporting to be from Immunovaccine. This press release states ... Gilead Science, Inc. The press release did not ... the information contained within the press release. Please ...
    (Date:2/27/2015)... CAMBRIDGE, Mass. , Feb. 27, 2015 /PRNewswire-USNewswire/ ... Analysis of the NCATS rare-diseases portfolio " in ... of a new financing technique to reduce the ... new diseases and potentially unlock new levels of ... The product of a unique collaboration between ...
    (Date:2/27/2015)... 2015 The fully automated supercritical ... can sequentially analyze up to 48 samples utilizing ... detection of targets by mass spectrometry. , ... the measurement requirements of a wide range of ... delivery and search for disease biomarkers, additives in ...
    Breaking Biology Technology:Outside GC Expands Healthcare Team 2Immunovaccine Disclaims Hoax Press Release 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 3
    ... NeoStem, Inc.,(NYSE Alternext US: NBS), which is pioneering the pre-disease ... medical need,today announced that it has completed an above market ... $1.25 per unit with each unit,consisting of one share of ... stock at $1.75 per share. , ...
    ... SAN FRANCISCO, Calif., Dec. 3 Portola,Pharmaceuticals, a ... in cardiovascular disease, inflammatory disease,and cancer, today announced ... novel,compounds that inhibit spleen tyrosine kinase (Syk) and ... presented at the annual meeting of the,American Society ...
    ... , , QUEBEC CITY, ... AEZS ; TSX: AEZ), a global biopharmaceutical company ... has completed the transaction under the previously announced purchase ... ("CHRP") relating to AEterna Zentaris, rights to royalties on ...
    Cached Biology Technology:NeoStem Completes $500,000 Private Placement With Strategic Investor 2NeoStem Completes $500,000 Private Placement With Strategic Investor 3Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting 2Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting 3AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners 2AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners 3
    (Date:1/22/2015)... Showcase, Hall E -   EyeLock Inc. , a market ... showcase its EyeLock ID technology integrated in a 3D printed ... Oak Ridge National Laboratory (ORNL) at the 2015 ... technology is being used to validate the driver and authorize ...
    (Date:1/22/2015)... Jan. 16, 2015  A man-made form of insulin delivered ... mental capabilities in adults with mild cognitive impairment and ... by researchers at Wake Forest Baptist Medical Center. ... amnesic mild cognitive impairment (MCI) or mild to moderate ...
    (Date:1/22/2015)... and POINT ROBERTS, Washington , ... source covering leading sectors including technology and tech stocks, releases ... marketplace featuring master pickpocket and security consultant Apollo Robbins ... stolen and talks about the Wocket™ biometric smart wallet, a ...
    Breaking Biology News(10 mins):EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3
    ... a unique vulnerability that can be exploited to make ... Washington University School of Medicine in St. Louis report. ... that tumors have a built-in mechanism that protects them ... benefit of hyperthermia and radiation as a combined therapy. ...
    ... way to rejuvenate dead nerve endings and a device ... among this years nine winners at NJITs annual provosts ... I walk through this showcase is the sophisticated array ... undergraduate students, said NJIT Provost Priscilla P. Nelson. ...
    ... the US, many people believe that the recent proliferation of ... people aim to significantly reduce the amount of saturated fats ... healthier, and happier. However, many leading researchers in the medical ... In FAT: ITS NOT WHAT YOU THINK (Prometheus, $15.95), technical ...
    Cached Biology News:Researchers find way to make tumor cells easier to destroy 2NJIT applauds students for studies on brain injury, glaucoma and more 2Fat: Its not what you think! 2
    Mouse monoclonal [002-49] to C1s ( Abpromise for all tested applications). entrezGeneID: 716 SwissProtID: P09871...
    Goat polyclonal to HSPC150 ( Abpromise for all tested applications). entrezGeneID: 29089...
    Oct 2 Immunogen: Full length human protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
    Mouse monoclonal [3B6] to HSV1 + HSV2 ICP5 Major Capsid Protein ( Abpromise for all tested applications)....
    Biology Products: